WO2004103266A3 - Protein kinase c peptides for use in withdrawal - Google Patents

Protein kinase c peptides for use in withdrawal Download PDF

Info

Publication number
WO2004103266A3
WO2004103266A3 PCT/US2003/016070 US0316070W WO2004103266A3 WO 2004103266 A3 WO2004103266 A3 WO 2004103266A3 US 0316070 W US0316070 W US 0316070W WO 2004103266 A3 WO2004103266 A3 WO 2004103266A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
protein kinase
withdrawal
isozyme
pkc
Prior art date
Application number
PCT/US2003/016070
Other languages
French (fr)
Other versions
WO2004103266A8 (en
WO2004103266A2 (en
Inventor
Daria Mochly-Rosen
Joan J Kendig
Sarah M Sweitzer
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Priority to PCT/US2003/016070 priority Critical patent/WO2004103266A2/en
Priority to AU2003241559A priority patent/AU2003241559A1/en
Priority to JP2004572186A priority patent/JP4675109B2/en
Priority to EP03731305A priority patent/EP1631309A4/en
Priority to CA002524818A priority patent/CA2524818A1/en
Publication of WO2004103266A2 publication Critical patent/WO2004103266A2/en
Publication of WO2004103266A3 publication Critical patent/WO2004103266A3/en
Publication of WO2004103266A8 publication Critical patent/WO2004103266A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Abstract

A composition for use in managing withdrawal from an addictive substance is described. The composition includes one or more peptides having specific activity for the ∈ and/or Ϝ isozyme of protein kinase C (PKC). The peptide(s) can be administered prior to, concurrent with, or subsequent to administration of the addictive substance. Also described is a kit having at least one container containing a peptide having isozyme-specific activity for ∈PKC or ϜPKC and instructions for use.
PCT/US2003/016070 2003-05-16 2003-05-16 Protein kinase c peptides for use in withdrawal WO2004103266A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/US2003/016070 WO2004103266A2 (en) 2003-05-16 2003-05-16 Protein kinase c peptides for use in withdrawal
AU2003241559A AU2003241559A1 (en) 2003-05-16 2003-05-16 Protein kinase c peptides for use in withdrawal
JP2004572186A JP4675109B2 (en) 2003-05-16 2003-05-16 Protein kinase C peptide for use in withdrawal symptoms
EP03731305A EP1631309A4 (en) 2003-05-16 2003-05-16 Protein kinase c peptides for use in withdrawal
CA002524818A CA2524818A1 (en) 2003-05-16 2003-05-16 Protein kinase c peptides for use in withdrawal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/016070 WO2004103266A2 (en) 2003-05-16 2003-05-16 Protein kinase c peptides for use in withdrawal

Publications (3)

Publication Number Publication Date
WO2004103266A2 WO2004103266A2 (en) 2004-12-02
WO2004103266A3 true WO2004103266A3 (en) 2005-03-24
WO2004103266A8 WO2004103266A8 (en) 2005-10-20

Family

ID=33476226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016070 WO2004103266A2 (en) 2003-05-16 2003-05-16 Protein kinase c peptides for use in withdrawal

Country Status (5)

Country Link
EP (1) EP1631309A4 (en)
JP (1) JP4675109B2 (en)
AU (1) AU2003241559A1 (en)
CA (1) CA2524818A1 (en)
WO (1) WO2004103266A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001805A1 (en) * 1998-07-06 2000-01-13 Messing Robert O Cells and animals deficient in protein kinase c epsilon
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
US20030223981A1 (en) * 2002-04-22 2003-12-04 Daria Mochly-Rosen Peptide inhibitors of protein kinase C gamma for pain management

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140716A0 (en) * 1998-07-06 2002-02-10 Use of inhibitors of protein kinase c epsilon to treat pain
AU5116099A (en) * 1998-07-21 2000-02-14 Sui Xiong Cai Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001805A1 (en) * 1998-07-06 2000-01-13 Messing Robert O Cells and animals deficient in protein kinase c epsilon
US20020124272A1 (en) * 1998-07-06 2002-09-05 Robert O. Messing Protein kinase c epsilon as modulator of anxiety, alcohol consumption and self-administration of drugs of abuse
US6376467B1 (en) * 1998-10-09 2002-04-23 The Regents Of The University Of California Use of inhibitors of protein kinase C epsilon to treat pain
US20030223981A1 (en) * 2002-04-22 2003-12-04 Daria Mochly-Rosen Peptide inhibitors of protein kinase C gamma for pain management

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHNSON, J.A. ET AL.: "A Protein Kinase C Translocation Inhibitor as an Isozyme-Selective Antagonist of Cardiac Function", J. BIOL. CHEM., vol. 271, no. 40, 4 October 1996 (1996-10-04), pages 24962 - 24966, XP000867211 *
See also references of EP1631309A4 *

Also Published As

Publication number Publication date
WO2004103266A8 (en) 2005-10-20
EP1631309A2 (en) 2006-03-08
JP2006525948A (en) 2006-11-16
EP1631309A4 (en) 2010-04-28
WO2004103266A2 (en) 2004-12-02
JP4675109B2 (en) 2011-04-20
AU2003241559A1 (en) 2004-12-13
CA2524818A1 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
YU29901A (en) Utilisation of dialkylfumarates
DE60222907D1 (en) TANK ASSEMBLY SYSTEM WITH MULTIPLE FAN
WO2004052401A3 (en) Compositions and methods of delivery of pharmacological agents
WO2006014320A3 (en) Iv administration set identification system
WO2003028757A1 (en) Novel method of inducing antigen-specific t cells
EP1757289A4 (en) Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
CL2010000816A1 (en) Formulation suitable for subcutaneous administration comprising at least 100 mg / ml of ctlaig, a sugar, and a pharmaceutically stable aqueous carrier; article of manufacture comprising at least one container containing the aforementioned formulation. (divisional application n ° 3597-06)
BR0014486A (en) Pharmaceutical compositions containing stabilized liquid polypeptide
ATE482717T1 (en) PEPTIDE YY (PYY) FOR THE TREATMENT OF GLUCOSE METABOLIC DISEASES
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2003028758A1 (en) Novel method of inducing antigen-specific t cells
WO2006057003A3 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
IL173369A0 (en) Pharmaceutical combination of g-csf and plgf useful for blood stem cell
WO2006056998A3 (en) Methods of cell therapy, neurogenesis and oligodendrogenesis
WO2008070721A3 (en) High protein concentration formulations containing mannitol
MXPA06000243A (en) Stable tetrodotoxin freeze drying medicinal preparation.
ATE350024T1 (en) LIQUID PREPARATION CONTAINING TOBRAMYCIN
MY136546A (en) A pharmaceutical component based on human parathyroid harmone and a pharmaceutical composition for intranasal administration comprising the component
WO2004103266A8 (en) Protein kinase c peptides for use in withdrawal
WO2001028576A3 (en) NON-MAMMALIAN GnRH ANALOGS AND USES THEREOF IN REGULATION OF FERTILITY AND PREGNANCY
Teixeira et al. Pharmacological characterization of kinin‐induced relaxation of human corpus cavernosum
EP1099439A3 (en) Use of apo B secretion/MTP inhibitors
WO2008151606A3 (en) Device for storing and administering active substances
AU2002360885A1 (en) Storage device for consumption-dependent reception of medicaments
EP1099438A3 (en) Use of APO B secretion/MTP inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2003241559

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2524818

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004572186

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003731305

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003731305

Country of ref document: EP